Method for assaying sepsis in humans

Patent metadata

Field	Value
Publication number	US-9857381-B2
Application number	US-201313853514-A
Country	US
Kind code	B2
Filing date	Mar 29, 2013
Priority date	Sep 7, 2007
Publication date	Jan 2, 2018
Grant date	Jan 2, 2018

Abstract

The present invention relates to a reliable method of prediction of sepsis in humans after a trauma, wherein the level of pancreatic stone protein/regenerating protein (PSP/reg) is determined in serum, and a high level is indicative of the development of sepsis at early stages of the disease. Furthermore a method of determination of PSP/reg levels in serum is described.

First claim

What we claim is:

1. A method of quantifying pancreatic stone protein/regenerating protein (PSP/reg) in a serum sample comprising:
(a) obtaining the serum sample from a human who suffered from trauma 3, 4 or 5 days after said trauma, wherein the human did not suffer from pancreatic injury, and
(b) detecting an increased level of PSP/reg by measuring a level of PSP/reg that is higher than 60 ng/ml in said serum sample, wherein said measuring is performed by contacting the serum sample with an antibody against PSP/reg, and
(c) treating said human having a level of PSP/reg higher than 60 ng/ml by administering an antibiotic to treat sepsis.

2. The method of claim 1 , wherein said human is monitored for sepsis.

3. The method of claim 1 , wherein the level of PSP/reg is above 80 ng/ml.

4. The method of claim 1 , wherein the level of PSP/reg is detected by ELISA, RIA, EIA, mass spectrometry, or microarray analysis.

5. The method of claim 1 , wherein the level of PSP/reg is detected via a sandwich ELISA, comprising:
providing microtiter plates coated with a first antibody directed against PSP/reg,
blocking said plates,
loading the sample onto said plates,
applying a second antibody against PSP/reg in the sample,
adding a third antibody that detects the second antibody, wherein said third antibody is conjugated with a label, and
adding a substrate for the label to detect and quantify the label.

6. The method of claim 5 , wherein the label is an enzyme for chromogenic detection and the substrate is a color-generating substrate of the conjugated enzyme.

7. The method of claim 5 , wherein the first antibody and the second antibody against PSP/reg in the sample are polyclonal antibodies.

8. The method of claim 1 , wherein the binding between said antibody and PSP/reg is detected and said antibody is a polyclonal antibody raised in an animal.

9. The method of claim 8 , wherein said antibody is obtained from mice, rats, rabbits, goats, chicken, donkey, horses or guinea pigs.

10. The method of claim 1 , wherein a pair of guinea pig, rat, mouse, rabbit, goat, chicken, donkey or horse antibodies is provided in said detecting PSP/reg and wherein one of said antibodies of said pair is against PSP/reg.

11. The method of claim 1 , wherein a single antibody against PSP/reg is provided in said detecting PSP/reg and binding of said single antibody to PSP/reg is detected via chemiluminescence detection on automated commercial analytical robots,
microparticle enhanced fluorescence,
fluorescence polarized methodologies,
or mass spectrometry.

12. The method of claim 1 , wherein a single antibody against PSP/reg is provided in said detecting PSP/reg, said single antibody is a guinea pig, rat, mouse, rabbit, goat, chicken, donkey or horse antibody and binding of said single antibody to PSP/reg is detected.

Assignees

• Univ Zuerich

Inventors

• Graf Rolf
• Bimmler Daniel
• Keel Marius

Classifications

• G01N2800/26

  Infectious diseases, e.g. generalised sepsis · CPC title

• G01N2333/474

  Pancreatic thread protein; Reg protein · CPC title

• G01N33/6893 Primary

  related to diseases not provided for elsewhere · CPC title